AppFolio second quarter revenues up, net loss down
AppFolio raised its financial outlook for the year as revenues increased sharply and losses narrowed in the second quarter, the company said Aug. 8. AppFolio, a Goleta-based developer of property management software for small- to medium-sized property managers, raised full-year financial-guidance estimates to a range between $103 million and $105 million Aug. 8. Previous estimates Read More →
Read More →Inphi’s second quarter revenues soar
Inphi saw revenues rise during the second quarter as it sold off its memory products business. On June 30, Inphi announced it would sell its memory products business to Sunnyvale-based Rambus. Inphi said revenues rose from $49.4 million in 2015 to $60.5 million during the second quarter of 2016 when revenues from the memory business Read More →
Read More →Santa Barbara’s Aurrion acquired for $165 million
Sunnyvale-based Juniper Networks announced Aug. 4 in a quarterly filing with the Securities and Exchange Commission it acquired Santa Barbara-based silicon photonic chip maker Aurrion for $165 million. Aurrion makes components that transmit information quickly using cheap, easily mass-produced silicon wafers. UC Santa Barbara professor John Bowers founded Aurrion in 2008 and the company quickly Read More →
Read More →Abbvie sues Amgen to block sales of Humira biosimilar
Thousand Oaks-based biotech giant Amgen faces a lawsuit seeking to block it from selling a biosimilar of AbbVie’s popular Humira. The rheumatoid arthritis medicine is Abbvie’s best seller. Sales were up 17 percent in the second quarter to $4.15 billion and accounted for 61 percent of AbbVie’s 2015 revenue. Abbvie claims Amgen’s proposed copy would Read More →
Read More →ThermaPure CEO takes reins after dad dies of cancer
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Silence is deafening when new drugs are not approved
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →